MBX Biosciences, Inc. Common Stock
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Carmel, Indiana, develops novel precision endocrine peptide (PEP) therapies utilizing its proprietary PEP platform to treat endocrine and metabolic disorders including hypoparathyroidism, post-bariatric hypoglycemia, and obesity; its lead product candidate, canvuparatide (MBX 2109), a long-acting parathyroid hormone (PTH) peptide prodrug delivered via once-weekly subcutaneous injection, advances in Phase 2 Avail trial for chronic hypoparathyroidism following positive Phase 1 data showing sustained serum calcium elevation, low peak-to-trough ratios, and good tolerability, with Phase 3 initiation planned for 2026; imapextide (MBX 1416), a long-acting GLP-1 receptor antagonist, progresses in Phase 2 for post-bariatric hypoglycemia after Phase 1 pharmacokinetics supporting weekly dosing; MBX 4291, a potent GLP-1/GIP co-agonist prodrug, enters Phase 1 for obesity targeting once-monthly administration with preclinical weight loss comparable to tirzepatide at lower concentrations, alongside additional preclinical programs in rare and prevalent endocrine diseases. The company operates primarily in the United States with a discovery pipeline leveraging advanced chemical modifications, programmable prodrug technologies, and fatty acylation for optimized potency, selectivity, half-life, and tolerability. Recent developments include its initial public offering and upsized follow-on offering in September 2024 raising over $200 million gross proceeds for a cash position of $391.7 million as of September 30, 2025 funding operations into 2029; positive topline Phase 2 Avail results in Q3 2025; a $63.5 million Series C financing in August 2024; executive appointments such as Chief Medical Officer Salomon Azoulay in June 2024 and Chief Scientific Officer Steven Prestrelski in 2023; FDA IND clearance for MBX 1416 in 2023; and $115 million Series B financing in 2022.
Company News
Microbix Attending & Presenting at IPVS 2026
MBX Biosciences to Participate in Upcoming November Investor Conferences
MBX Biosciences (NASDAQ:MBX) Shares Climb 4.1% – Time to Buy?
MBX Biosciences, Inc. $MBX Shares Newly Bought by Bank of America Corp DE
MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade)
MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH
Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH?
MBX Biosciences to Participate in Upcoming Investor Conferences
MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer
Jupiter Topco LLC Acquires Shares of 10,300 MBX Biosciences, Inc. $MBX
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
Microbix Reports Results for Q3 Fiscal 2026
MBX Biosciences (NASDAQ:MBX) Reaches New 12-Month High After Analyst Upgrade
MBX Biosciences (NASDAQ:MBX) Hits New 12-Month High – Here’s Why
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) vs. MBX Biosciences (NASDAQ:MBX) Critical Survey
MBX Biosciences Announces Executive Leadership Transition to Support the Company's Next Phase of Growth
MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)
MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript
MBX Biosciences Highlights Sustained Calcium Control In Rare Disease